Novavax, Inc. (NVAX)
| Previous Close | 58.43 |
| Open | 55.71 |
| Bid | 53.51 x 1800 |
| Ask | 53.80 x 900 |
| Day's Range | 48.75 - 56.91 |
| 52 Week Range | 41.33 - 277.80 |
| Volume | |
| Avg. Volume | 4,656,451 |
| Market Cap | 4.039B |
| Beta (5Y Monthly) | 1.33 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -14.95 |
| Earnings Date | Feb 28, 2022 - Mar 04, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 183.40 |
- Motley Fool
Better Buy Ahead of FDA Meetings: Moderna vs. Novavax
Moderna (NASDAQ: MRNA) and Novavax (NASDAQ: NVAX) both delivered major returns for investors in the early days of the coronavirus vaccine race. Moderna's vaccine entered the market in December of 2020. Novavax's vaccine began winning authorizations a year later -- but isn't yet approved in the United States.
- Motley Fool
Why Novavax Stock Is Tumbling Today
What happened Shares of Novavax (NASDAQ: NVAX) were tumbling 9.7% as of 11:28 a.m. ET on Tuesday. The company didn't make any announcements that would explain the decline. Instead, Novavax's fall appears to be primarily a result of the overall stock market turmoil with all of the major market indexes sinking today.
- Motley Fool
3 Deeply Discounted Stocks You'll Wish You Bought on the Dip
Since the curtains opened on 2022, the iconic Dow Jones Industrial Average, benchmark S&P 500, and growth-focused Nasdaq Composite, have respective fallen by 14%, 18%, and 27%. Losing more than a quarter of its value has pushed the Nasdaq firmly into a bear market. Although a tumbling stock market can be scary and tug on investors' emotions, big declines have always represented a buying opportunity.
